Studies of rhodium(II) carboxylates as potential antitumor agents.
D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001665:Binding Sites; D002250:Carbon Radioisotopes; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004254:DNA Nucleotidyltransferases / Q000037:antagonists & inhibitors; D004273:DNA, Neoplasm / Q000096:biosynthesis; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D003864:Depression, Chemical; D005260:Female; D007928:Lethal Dose 50; D051379:Mice; D011119:Polynucleotides / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000378:metabolism; D012238:Rhodium / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D000085:Acetates; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D011119:Polynucleotides; D011422:Propionates; D011687:Purines; D014316:Tritium; D004247:DNA; D012238:Rhodium; D004254:DNA Nucleotidyltransferases; D012321:DNA-Directed RNA Polymerases; D013936:Thymidine